Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Valeant can have Zoetis, Bayer says. We have our hands full already

June 30, 2015
Life sciences
Whether animal health leader Zoetis receives any more buyout offers after Valeant’s reported approach remains to be seen. But if it does, Bayer’s leaders insist a competing bid won’t be coming from them.
 
As the German pharma’s management told Bernstein analyst Ronny Gal last week, it weighed buying Zoetis against picking up Merck’s OTC unit last year–and it decided to go after the latter, which it agreed to snag last May for $14.2 billion.
 
Bayer has long considered beefing up its animal health ops, but as CEO Marijn Dekkers put it last month, “it hasn’t happened with us yet.” The company considered snapping up Novartis’ veterinary business before Eli Lilly grabbed it last year, and it also contemplated a move for Zoetis back before Pfizer made clear that it intended to spin the business off. Before Dekkers’ time, now-Chairman Werner Wenning bid unsuccessfully for Schering-Plough’s animal health unit.
 
So when the Leverkeusen-based drugmaker announced plans to divest its plastics business–a move that would generate some extra dough–analysts speculated this could finally be the time, and speculators pegged $25 billion company Zoetis as a likely target.
 
Bayer has already gone on somewhat of an M&A spree lately, though, which would make a large acquisition right now “challenging,” Gal wrote. Shortly before inking the Merck consumer health pact, Bayer bought up another OTC company in China’s Dihon Pharmaceutical. All told, it’s got $21 billion in debt and $13.5 billion in pension liabilities and thus “is a bit starched financially right now,” Gal said.
 
Canada’s Valeant, though, hasn’t let its recent deals stop it from pursuing Zoetis, according to The Wall Street Journal. The serial acquirer–whose former deal partner, Bill Ackman, has been leveraging investor pressure on Zoetis since acquiring a stake last fall–has approached Zoetis about a potential buyout, the newspaper reported last week.
 
By Carly Helfand  
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach